{"transactions":[{"id":725614,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T21:44:57.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan (the \"Plan\"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":19000,"derivative":{"exercise_price":14.19,"expiration_date":"2036-06-25","underlying":"Class A Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001628280-26-045841","document":"wk-form4_1782510295.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855175/000162828026045841/wk-form4_1782510295.xml","form_type":"4"}},{"id":798582,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-28T20:31:18.000Z","date":"2026-04-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9174,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. (\"Company\"), Gilead Sciences, Inc. (\"Parent\"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option (\"Company Option\"), whether or not vested, and which had a per share exercise price less than $115 per share (the \"Closing Amount\"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. (\"Company\"), Gilead Sciences, Inc. (\"Parent\"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option (\"Company Option\"), whether or not vested, and which had a per share exercise price less than $115 per share (the \"Closing Amount\"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"exercise_price":63.68,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":9174},"source":{"system":"sec-edgar","filing":"0001663771-26-000002","document":"form4-04282026_080414.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1663771/000166377126000002/form4-04282026_080414.xml","form_type":"4"}},{"id":798581,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-28T20:31:18.000Z","date":"2026-04-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8011,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. (\"Company\"), Gilead Sciences, Inc. (\"Parent\"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option (\"Company Option\"), whether or not vested, and which had a per share exercise price less than $115 per share (the \"Closing Amount\"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. (\"Company\"), Gilead Sciences, Inc. (\"Parent\"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option (\"Company Option\"), whether or not vested, and which had a per share exercise price less than $115 per share (the \"Closing Amount\"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"exercise_price":51.3,"expiration_date":"2034-05-28","underlying":"Common Stock","underlying_shares":8011},"source":{"system":"sec-edgar","filing":"0001663771-26-000002","document":"form4-04282026_080414.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1663771/000166377126000002/form4-04282026_080414.xml","form_type":"4"}},{"id":798580,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-28T20:31:18.000Z","date":"2026-04-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11459,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. (\"Company\"), Gilead Sciences, Inc. (\"Parent\"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option (\"Company Option\"), whether or not vested, and which had a per share exercise price less than $115 per share (the \"Closing Amount\"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. (\"Company\"), Gilead Sciences, Inc. (\"Parent\"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option (\"Company Option\"), whether or not vested, and which had a per share exercise price less than $115 per share (the \"Closing Amount\"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"exercise_price":37.94,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":11459},"source":{"system":"sec-edgar","filing":"0001663771-26-000002","document":"form4-04282026_080414.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1663771/000166377126000002/form4-04282026_080414.xml","form_type":"4"}},{"id":798579,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-28T20:31:18.000Z","date":"2026-04-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":36806,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. (\"Company\"), Gilead Sciences, Inc. (\"Parent\"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option (\"Company Option\"), whether or not vested, and which had a per share exercise price less than $115 per share (the \"Closing Amount\"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. (\"Company\"), Gilead Sciences, Inc. (\"Parent\"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option (\"Company Option\"), whether or not vested, and which had a per share exercise price less than $115 per share (the \"Closing Amount\"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"exercise_price":7.61,"expiration_date":"2032-05-16","underlying":"Common Stock","underlying_shares":36806},"source":{"system":"sec-edgar","filing":"0001663771-26-000002","document":"form4-04282026_080414.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1663771/000166377126000002/form4-04282026_080414.xml","form_type":"4"}},{"id":1101135,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2025-06-26T21:41:51.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":14750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan (the \"Plan\"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 14,750 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2026, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":14750,"derivative":{"exercise_price":4.01,"expiration_date":"2035-06-25","underlying":"Class A Common Stock","underlying_shares":14750},"source":{"system":"sec-edgar","filing":"0001437749-25-021366","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855175/000143774925021366/rdgdoc.xml","form_type":"4"}},{"id":1128876,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-30T20:14:52.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":9174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the 2022 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of May 29, 2026 or the next annual meeting of stockholders."}],"balance_after":9174,"derivative":{"exercise_price":63.68,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":9174},"source":{"system":"sec-edgar","filing":"0001415889-25-014986","document":"form4-05302025_080559.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1663771/000141588925014986/form4-05302025_080559.xml","form_type":"4"}},{"id":1280279,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-06T15:56:26.000Z","date":"2025-02-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each Issuer restricted stock award held by a non-employee member of the Issuer board then outstanding and not vested was canceled and converted into the right to receive the Per Share Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-015354","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000095017025015354/ownership.xml","form_type":"4"}},{"id":1280278,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-06T15:56:26.000Z","date":"2025-02-04","kind":"other","planned":false,"acquired":false,"shares":16675,"price":3.65,"value":60863.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the \"Merger Agreement\"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation (\"Parent\"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"Merger Sub,\" and together with Parent, the \"Buyer Parties\"), pursuant to which Merger Sub completed a cash tender offer (the \"Offer\") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the \"Shares\"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the \"Per Share Price\"). These Issuer Shares were tendered for purchase pursuant to the Offer."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0000950170-25-015354","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000095017025015354/ownership.xml","form_type":"4"}},{"id":1488017,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-06T20:18:55.000Z","date":"2024-05-28","kind":"grant","planned":false,"acquired":true,"shares":8011,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the 2022 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of May 28, 2025 or the next annual meeting of stockholders."}],"balance_after":8011,"derivative":{"exercise_price":51.3,"expiration_date":"2034-05-28","underlying":"Common Stock","underlying_shares":8011},"source":{"system":"sec-edgar","filing":"0001415889-24-015745","document":"form4-06062024_080651.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1663771/000141588924015745/form4-06062024_080651.xml","form_type":"4"}},{"id":1499283,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2024-05-29T21:55:33.000Z","date":"2024-05-24","kind":"grant","planned":false,"acquired":true,"shares":3700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan, pursuant to the Issuer's Non-Employee Director Compensation Program, as amended. One-third of the option shares vest on April 5, 2025, and the remainder vests in 24 equal monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":3700,"derivative":{"exercise_price":15.76,"expiration_date":"2034-05-23","underlying":"Class A Common Stock","underlying_shares":3700},"source":{"system":"sec-edgar","filing":"0001437749-24-018621","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855175/000143774924018621/rdgdoc.xml","form_type":"4"}},{"id":1528123,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-03T08:47:58.000Z","date":"2024-05-01","kind":"grant","planned":false,"acquired":true,"shares":23458,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option shall vest on the earlier of (a) the one year anniversary, May 1, 2025 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to the Director's Continuous Service through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy."}],"balance_after":23458,"derivative":{"exercise_price":3.795,"expiration_date":"2034-04-30","underlying":"Common Stock","underlying_shares":23458},"source":{"system":"sec-edgar","filing":"0001479290-24-000090","document":"wk-form4_1714740469.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929024000090/wk-form4_1714740469.xml","form_type":"4"}},{"id":1528122,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-03T08:47:58.000Z","date":"2024-05-01","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annual restricted stock award (the \"RSA\") granted pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy (the \"Compensation Policy\").  The shares underlying the RSA shall vest on the earlier of (a) the one year anniversary, May 1, 2025 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to the Director's Continuous Service (as defined in the Company's 2014 Equity Incentive Plan (the \"Plan\")) through such vesting date."}],"balance_after":31675,"source":{"system":"sec-edgar","filing":"0001479290-24-000090","document":"wk-form4_1714740469.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929024000090/wk-form4_1714740469.xml","form_type":"4"}},{"id":1539073,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-18T20:01:16.000Z","date":"2024-04-16","kind":"exercise","planned":true,"acquired":false,"shares":9402,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the shares subject to the option will vest each year following Equity Grant Date on the same day of the month as the Equity Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years. \"Equity Grant Date\" shall mean May 16, 2022."}],"balance_after":36806,"derivative":{"exercise_price":7.61,"expiration_date":"2032-05-16","underlying":"Common Stock","underlying_shares":9402},"source":{"system":"sec-edgar","filing":"0001415889-24-011120","document":"form4-04182024_080409.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1663771/000141588924011120/form4-04182024_080409.xml","form_type":"4"}},{"id":1539072,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-18T20:01:16.000Z","date":"2024-04-16","kind":"sale","planned":true,"acquired":false,"shares":2612,"price":56.031,"value":146352.972,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on December 15, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average share price of an aggregate total of 2,612 shares sold in the price range of $55.87 to $56.8699 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-24-011120","document":"form4-04182024_080409.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1663771/000141588924011120/form4-04182024_080409.xml","form_type":"4"}},{"id":1539071,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-18T20:01:16.000Z","date":"2024-04-16","kind":"sale","planned":true,"acquired":false,"shares":6790,"price":55.3618,"value":375906.622,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on December 15, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 6,790 shares sold in the price range of $54.87 to $55.8699 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":2612,"source":{"system":"sec-edgar","filing":"0001415889-24-011120","document":"form4-04182024_080409.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1663771/000141588924011120/form4-04182024_080409.xml","form_type":"4"}},{"id":1539070,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-18T20:01:16.000Z","date":"2024-04-16","kind":"exercise","planned":true,"acquired":true,"shares":9402,"price":7.61,"value":71549.22,"ownership":{"direct":true},"balance_after":9402,"source":{"system":"sec-edgar","filing":"0001415889-24-011120","document":"form4-04182024_080409.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1663771/000141588924011120/form4-04182024_080409.xml","form_type":"4"}},{"id":1571881,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-18T22:38:08.000Z","date":"2024-03-15","kind":"exercise","planned":true,"acquired":false,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the shares subject to the option will vest each year following Equity Grant Date on the same day of the month as the Equity Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years. \"Equity Grant Date\" shall mean May 16, 2022."}],"balance_after":46208,"derivative":{"exercise_price":7.61,"expiration_date":"2032-05-16","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001415889-24-008340","document":"form4-03182024_100301.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1663771/000141588924008340/form4-03182024_100301.xml","form_type":"4"}},{"id":1571880,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-18T22:38:08.000Z","date":"2024-03-15","kind":"sale","planned":true,"acquired":false,"shares":3337,"price":70.9863,"value":236881.2831,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on December 15, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average share price of an aggregate total of 3,337 shares sold in the price range of $70.84 to $71.8399 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-24-008340","document":"form4-03182024_100301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1663771/000141588924008340/form4-03182024_100301.xml","form_type":"4"}},{"id":1571879,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-18T22:38:08.000Z","date":"2024-03-15","kind":"sale","planned":true,"acquired":false,"shares":3763,"price":70.361,"value":264768.443,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on December 15, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average share price of an aggregate total of 3,763 shares sold in the price range of $69.83 to $70.8299 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":3337,"source":{"system":"sec-edgar","filing":"0001415889-24-008340","document":"form4-03182024_100301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1663771/000141588924008340/form4-03182024_100301.xml","form_type":"4"}},{"id":1571878,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-18T22:38:08.000Z","date":"2024-03-15","kind":"sale","planned":true,"acquired":false,"shares":1900,"price":69.438,"value":131932.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on December 15, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 1,900 shares sold in the price range of $68.74 to $69.7399 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":7100,"source":{"system":"sec-edgar","filing":"0001415889-24-008340","document":"form4-03182024_100301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1663771/000141588924008340/form4-03182024_100301.xml","form_type":"4"}},{"id":1571877,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-18T22:38:08.000Z","date":"2024-03-15","kind":"exercise","planned":true,"acquired":true,"shares":9000,"price":7.61,"value":68490.0,"ownership":{"direct":true},"balance_after":9000,"source":{"system":"sec-edgar","filing":"0001415889-24-008340","document":"form4-03182024_100301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1663771/000141588924008340/form4-03182024_100301.xml","form_type":"4"}},{"id":1851285,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T20:23:36.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":11459,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the 2022 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 14, 2024 or the next annual meeting of stockholders."}],"balance_after":11459,"derivative":{"exercise_price":37.94,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":11459},"source":{"system":"sec-edgar","filing":"0001209191-23-037854","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1663771/000120919123037854/doc4.xml","form_type":"4"}},{"id":1902655,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2023-05-05T17:15:12.000Z","date":"2023-05-03","kind":"grant","planned":false,"acquired":true,"shares":5915,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option shall vest on the earlier of (a) the one year anniversary, May 3, 2024 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to Ms. Ware's Continuous Service through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy."}],"balance_after":5915,"derivative":{"exercise_price":33.61,"expiration_date":"2033-05-02","underlying":"Common Stock","underlying_shares":5915},"source":{"system":"sec-edgar","filing":"0001479290-23-000063","document":"wf-form4_168332129959439.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000063/wf-form4_168332129959439.xml","form_type":"4"}},{"id":1902654,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-05T17:15:12.000Z","date":"2023-05-03","kind":"grant","planned":false,"acquired":true,"shares":3534,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Represents an annual restricted stock award (the \"RSA\") granted pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy (the \"Compensation Policy\"). The shares underlying the RSA shall vest on the earlier of (a) the one year anniversary, May 3, 2024 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to Ms. Ware's Continuous Service (as defined in the Company's 2014 Equity Incentive Plan (the \"Plan\")) through such vesting date."}],"balance_after":16675,"source":{"system":"sec-edgar","filing":"0001479290-23-000063","document":"wf-form4_168332129959439.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000063/wf-form4_168332129959439.xml","form_type":"4"}},{"id":2267295,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-17T21:14:26.000Z","date":"2022-05-16","kind":"grant","acquired":true,"shares":55208,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the shares subject to the option will vest each year following Equity Grant Date on the same day of the month as the Equity Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years.  \"Equity Grant Date\" shall mean May 16, 2022."}],"balance_after":55208,"derivative":{"exercise_price":7.61,"expiration_date":"2032-05-16","underlying":"Common Stock","underlying_shares":55208},"source":{"system":"sec-edgar","filing":"0001209191-22-029759","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1663771/000120919122029759/doc4.xml","form_type":"4"}},{"id":2271984,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2022-05-13T18:16:15.000Z","date":"2022-05-04","kind":"grant","acquired":true,"shares":10756,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option shall vest on the one year anniversary, May 4, 2023, subject to Ms. Ware's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) through such vesting date. The stock option represents an annual grant pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy"}],"balance_after":10756,"derivative":{"exercise_price":18.12,"expiration_date":"2032-05-03","underlying":"Common Stock","underlying_shares":10756},"source":{"system":"sec-edgar","filing":"0001479290-22-000070","document":"wf-form4a_165248009386130.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929022000070/wf-form4a_165248009386130.xml","form_type":"4/A","original_submission_date":"2022-05-06"}},{"id":2279272,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2022-05-06T18:17:40.000Z","date":"2022-05-04","kind":"grant","acquired":true,"shares":11343,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option shall vest on the one year anniversary, May 4, 2023, subject to Ms. Ware's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy."}],"balance_after":11343,"derivative":{"exercise_price":18.12,"expiration_date":"2032-05-03","underlying":"Common Stock","underlying_shares":11343},"source":{"system":"sec-edgar","filing":"0001479290-22-000058","document":"wf-form4_165187544365949.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929022000058/wf-form4_165187544365949.xml","form_type":"4"}},{"id":2279271,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-06T18:17:40.000Z","date":"2022-05-04","kind":"grant","acquired":true,"shares":6059,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annual restricted stock award (the \"RSA\") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the \"Compensation Policy\").  The shares underlying the RSA shall vest on the one year anniversary, May 4, 2023, subject to Ms. Ware's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the \"Plan\")) through such vesting date."}],"balance_after":13141,"source":{"system":"sec-edgar","filing":"0001479290-22-000058","document":"wf-form4_165187544365949.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929022000058/wf-form4_165187544365949.xml","form_type":"4"}},{"id":2723092,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2021-05-07T19:23:20.000Z","date":"2021-05-05","kind":"grant","acquired":true,"shares":1268,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option shall vest on the one year anniversary, May 5, 2022, subject to Ms. Ware's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy."}],"balance_after":1268,"derivative":{"exercise_price":27.91,"expiration_date":"2031-05-04","underlying":"Common Stock","underlying_shares":1268},"source":{"system":"sec-edgar","filing":"0001479290-21-000118","document":"wf-form4_162042978578360.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929021000118/wf-form4_162042978578360.xml","form_type":"4"}},{"id":2723091,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-07T19:23:20.000Z","date":"2021-05-05","kind":"grant","acquired":true,"shares":674,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annual restricted stock award (the \"RSA\") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the \"Compensation Policy\").  The shares underlying the RSA shall vest on the one year anniversary, May 5, 2022, subject to Ms. Ware's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the \"Plan\")) through such vesting date."}],"balance_after":7082,"source":{"system":"sec-edgar","filing":"0001479290-21-000118","document":"wf-form4_162042978578360.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929021000118/wf-form4_162042978578360.xml","form_type":"4"}},{"id":2796915,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2021-03-10T19:13:48.000Z","date":"2021-03-08","kind":"grant","acquired":true,"shares":11161,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option shall vest on the one year anniversary of the date of grant, March 8, 2022, subject to Ms. Ware's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an initial grant pursuant to the Compensation Policy."}],"balance_after":11161,"derivative":{"exercise_price":24.03,"expiration_date":"2031-03-07","underlying":"Common Stock","underlying_shares":11161},"source":{"system":"sec-edgar","filing":"0001479290-21-000073","document":"wf-form4_161542161063629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929021000073/wf-form4_161542161063629.xml","form_type":"4"}},{"id":2796914,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-10T19:13:48.000Z","date":"2021-03-08","kind":"grant","acquired":true,"shares":6408,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an initial restricted stock award (the \"RSA\") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the \"Compensation Policy\").  The shares underlying the RSA shall vest on the one year anniversary of the date of grant, March 8, 2022, subject to Ms. Ware's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the \"Plan\")) through such vesting date."}],"balance_after":6408,"source":{"system":"sec-edgar","filing":"0001479290-21-000073","document":"wf-form4_161542161063629.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929021000073/wf-form4_161542161063629.xml","form_type":"4"}}]}